Jiangxi Kelun Pharmaceutical Co., Ltd. and Hubei Yinuokang Medical Technology Co., Ltd. agreed to acquire 49% stake in Wuhan Quanruinuo Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co.,Ltd. (SZSE:301075) for CNY 0 on January 19, 2024. As of September 30, 2023, in Wuhan Quanruinuo Pharmaceutical Technology Co., Ltd. generated total assets of CNY 3.1 million and net assets of CNY 3.1 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18.49 CNY | -1.96% | -4.15% | -30.67% |
1st Jan change | Capi. | |
---|---|---|
-30.67% | 202M | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.47% | 238B | |
+7.35% | 204B | |
-6.42% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- 301075 Stock
- News Tibet Duo Rui Pharmaceutical Co., Ltd.
- Jiangxi Kelun Pharmaceutical Co., Ltd. and Hubei Yinuokang Medical Technology Co., Ltd. agreed to acquire 49% stake in Wuhan Quanruinuo Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co.,Ltd. for CNY 0.